目的 探讨香连片联合美沙拉嗪治疗慢性溃疡性结肠炎的临床疗效。方法 选取2020年2月—2020年11月在天津医科大学总医院治疗的104例慢性溃疡性结肠炎患者，根据用药的差别分为对照组和治疗组，每组各52例。对照组口服美沙拉嗪肠溶片，0.5 g/次，3次/d。治疗组在对照组基础上口服香连片，1.5 g/次，3次/d。两组均经3个月治疗进行效果对比。观察两组患者临床疗效，比较治疗前后两组患者临床症状改善时间，IBDQ、SAS和Mayo评分，炎症介质C反应蛋白（CRP）、白细胞介素-8（IL-8）、白细胞介素-33（IL-33）和肿瘤坏死因子-α（TNF-α）水平，及肠道功能屏障。结果 经治疗，对照组和治疗组临床有效率分别为82.69%和98.08%，对照组明显低于治疗组（P<0.05）。经治疗，治疗组症状改善时间明显早于对照组（P<0.05）。经治疗，两组IBDQ评分明显升高，而SAS和Mayo评分显著降低（P<0.05），且治疗组明显好于对照组（P<0.05）。经治疗，两组血清CRP、IL-8、IL-33、TNF-α水平均明显下降（P<0.05），且治疗组更显著（P<0.05）。经治疗，两组D-乳酸、二胺氧化酶、内毒素水平均显著下降（P<0.05），且治疗组更明显（P<0.05）。结论 香连片联合美沙拉嗪治疗慢性溃疡性结肠炎可有效改善患者临床症状和疾病活动程度，降低机体炎症反应，促进肠道屏障功能的恢复，促进患者生活质量提高。

Objective To explore the clinical efficacy of Xianglian Tablets combined with mesalazine in treatment of chronic ulcerative colitis. Methods Patients (104 cases) with chronic ulcerative colitis in Tianjin Medical University General Hospital from February 2020 to November 2020 were divided into control and treatment groups based on different treatments, and each group had 52 cases. Patients in the control group were po administered with Mesalazine Enteric Coated Tablets, 0.5 g/time, three times daily. Patients in the treatment group were po administered with Xianglian Tablets on the basis of the control group, 1.5 g/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, the improvement time of clinical symptoms, IBDQ, SAS and Mayo scores, the inflammatory mediators CRP, IL-8, IL-33 and TNF-α, and the intestinal functional barrier in two groups before and after treatment were compared. Results After treatment, the clinical effective rates in the control group and the treatment group were 82.69% and 98.08% respectively, and which in the control group was significantly lower than that in the treatment group (P < 0.05). After treatment, the improvement time of symptoms in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, IBDQ scores in two groups were significantly increased, while SAS and Mayo scores were significantly decreased (P < 0.05), and these scores in the treatment group was significantly better than those in the control group (P < 0.05). After treatment, the serum CRP, IL-8, IL-33 and TNF-α levels in two groups were significantly decreased (P < 0.05), and which in the treatment group was significantly lower than those in the control group (P < 0.05). After treatment, the contents of D-lactate, diamine oxidase and endotoxin in two groups were significantly decreased (P < 0.05), and the decreasing ion the treatment group was the most obvious (P < 0.05). Conclusion Xianglian Tablets combined with mesalazine in treatment of chronic ulcerative colitis can effectively improve the clinical symptoms and disease activity of patients, reduce the body inflammatory reaction, promote the recovery of intestinal barrier function, and improve the quality of life of patients.

R975

天津市教委科研计划项目（2018KJ059）